ISA106 (SARS-CoV2)

COVID-19 is a new disease, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has not previously been seen in humans.

Patients with symptomatic infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can experience a range of clinical manifestations, from mild upper respiratory symptoms to critical illness.

ISA106 is an SLP immunotherapy designed to elicit a strong and specific T cell immune response against multiple SARS-CoV2 antigens, with the intention to clear an established infection. This therapy provides a treatment option for high risk patients that test positive for SARS-CoV2 infection and aims to prevent severe disease.

ISA106 is in late-stage preclinical development.